Medicine/s Name Dosage/s and Strength/s Remarks Issuance

250 mg, 500 mg, 750 mg, and 1 g film coated tablet

• 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial

• 100 mg/mL oral solution, 100 mL and 300 mL bottle

- Recommended for inclusion

- Indication: Control of generalized tonic-clonic status epilepticus, particularly in patients whom other anti-convulsants are contraindicated; control of generalized tonic-clonic seizures or focal seizures when oral anti-convulsants cannot be administered.

Department Memorandum no. 2019-0163

5 mg and 10 mg film coated tablet

- Recommended for inclusion

- Indication: For dementia, Alzheimer's disease, and vascular dementia

Department Memorandum no. 2019-0163

150 mg film coated tablet

- Recommended for inclusion

- Indication: For the treatment of latent tuberculosis infection (LTBI).

- Remarks: For use by the National Tuberculosis Control Program (NTP) of the Department of Health.

Department Memorandum no. 2019-0163
Tolvaptan 15 mg tablet

- Recommended for inclusion for the
following FDA-approved indications and usage:

a) Hyponatremia

Tolvaptan is indicated for the treatment of
patients with clinically significant
hypervolemic and euvolemic hyponatremia
(serum sodium < 125 mEq/L or less marked
hyponatremia that is symptomatic and has
resisted con‘ection with fluid restriction).
including those with heart failure, and
Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

Important Limitations:

Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not
be treated with tolvaptan. It has not been established that raising sentm sodium with tolvaptan provides a symptomatic benefit to patients

b) Adjunct Treatment of Volume Overload in Heart Failure

Volume overload in heart failure when adequate response is not obtainedi with other diuretics (e.g., loop diuretics).

Important Limitations:

Tolvaptan should be used in combination with other diuretics, such as loop diuretics, thiazides, and aldosterone antagonists.

Department Memorandum no. 2019-0033
0.9% Sodium Chloride Solution for Irrigation, 1000 mL, (1L) bottle

- Recommended for Inclusion 

- For inclusion as an additional preparation to the currently listed 0.9% Sodium Chloride solution for IV infusion.

Department Memorandum no. 2019-0033